Loading organizations...
§ Private Profile · 77 Geary St Fl 5, San Francisco, California, 94108, United States
Health tech company applying AI to personal health data for precision medicine and personalized support for chronic diseases, focusing on IBD.
San Francisco-based Gali Health is a health technology company that develops an artificial intelligence-driven mobile application to crowdsource personal health data and provide personalized disease management support for patients with chronic conditions. The software platform initially focuses on inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, by analyzing medical, lifestyle, and psychological metrics to generate medically validated clinical insights. Operating with a core team of five full-time employees, the enterprise generates less than $5 million in annual revenue and secured a $2 million seed funding round in 2019 to expand its precision medicine capabilities. The company is backed by venture capital firms including Felicis Ventures and Civilization Ventures, while maintaining strategic research and clinical partnerships with Stanford Hospital and UCSF. Gali Health was officially founded in 2015 by former NextBio executive Ilya Kupershmidt.
Gali Health has raised $5.0M across 2 funding rounds.
Gali Health has raised $5.0M in total across 2 funding rounds.
Gali Health has raised $5.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in May 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2020 | $3M Seed | — | ARCH Venture Partners, CentreGold Capital, Plug & Play Ventures, Julian Zegelman, BOB Nelson, Bold Capital Partners, Felicis Ventures, Tech Coast Angels, Silicon Valley Investors | Announced |
| Jun 1, 2019 | $2M Seed | Felicis Ventures | ARCH Venture Partners, Venrock | Announced |
Gali Health is a San Francisco-based health tech company developing an AI-powered mobile app called Gali, a personal health assistant that helps individuals with chronic conditions like inflammatory bowel disease (IBD) proactively manage their health.[1][2][3] It serves everyday users facing chronic illnesses by crowdsourcing personal health data, medically-validated insights, and applying AI for personalized support on medical, lifestyle, and psychological aspects, addressing feelings of isolation and powerlessness in healthcare.[1][2][3] The platform solves fragmented chronic disease management by integrating user data with collective intelligence, offering tailored suggestions, community support, and tools for preemptive health actions, with initial focus on IBD including Crohn's and Ulcerative Colitis.[1][3][5] Growth includes app launches on iOS, expansion from limited access programs, and initiatives like the IBD Footprints research program for multi-omic datasets to advance diagnostics and therapeutics.[3][5]
Gali Health emerged to tackle patient frustrations with chronic disease management in a strained healthcare system, where many turn to social media for support—74% of internet users seek health info there.[1] Founded as a consumer-focused health tech firm at the intersection of medicine, psychology, AI, social engineering, education, and media, it is based in San Francisco with a mission to advance precision medicine through crowdsourced data and AI.[2][3][6] Key early milestones include launching the Gali app for IBD patients free on iOS, validating via a Limited Access Program, and rolling it out to broader users, alongside the 2020 IBD Footprints research program combining mobile tracking, sample biobanking, and multidimensional sequencing for comprehensive datasets.[3][5] Specific founders are not detailed in available sources, but the company has pursued equity crowdfunding on platforms like SeedInvest.[1]
Gali Health rides the precision medicine and AI-driven personalization wave in health tech, where chronic diseases like IBD affect millions amid rising demand for patient-empowered tools—80% of social media health seekers highlight systemic gaps.[1][2] Timing aligns with booming digital health post-2020, accelerated by mobile AI adoption and multi-omics data needs for better therapeutics, as traditional systems fail at proactive, holistic (medical/lifestyle/psychological) support.[3][5] Market forces favoring it include exploding personal health data volumes, blockchain for privacy-secure sharing, and research shifts to longitudinal patient datasets, positioning Gali to influence ecosystem by bridging consumers, clinicians, and researchers for novel diagnostics.[4][5] It democratizes precision medicine beyond institutions, fostering data-driven breakthroughs in underserved chronic care.[2]
Gali Health is poised to expand beyond IBD into broader chronic conditions, scaling its "Healthomics" platform and Gali Brain through more research programs and partnerships for therapeutics development.[5] Trends like AI advancements in streaming ML, genomic integration, and tokenized data economies will amplify its growth, potentially disrupting employer-centric models by prioritizing consumer control.[1][4] Influence may evolve toward a full precision medicine ecosystem, enabling population-level insights while empowering individuals—reinforcing its core mission that no one faces disease alone, as AI and crowdsourced data redefine proactive health management.[2][3]
Gali Health has raised $5.0M in total across 2 funding rounds.
Gali Health's investors include ARCH Venture Partners, CentreGold Capital, Plug & Play Ventures, Julian Zegelman, Bob Nelson, Bold Capital Partners, Felicis Ventures, Silicon Valley Investors, Venrock.